Clinical Report: Rethinking Value, Access, and Affordability in Cell and Gene Therapy
Background
Cell and gene therapies have the potential to alter the treatment landscape for serious diseases. However, high manufacturing costs, complex delivery systems, and uncertain reimbursement models pose barriers to patient access. Addressing these challenges is critical for the integration of these therapies into standard care.
Data Highlights
No numerical data or trial data was provided in the source material.
Key Findings
- High manufacturing costs and complex delivery pathways restrict patient access to cell and gene therapies.
- Industry leaders advocate for reducing production costs and treating patients earlier in the disease process.
- Expanding delivery beyond specialist centers is essential for improving access.
- Long-term value assessment of therapies should be prioritized over upfront pricing.
- Collaboration among manufacturers, regulators, healthcare systems, payers, and patient advocates is necessary for sustainable access.
Clinical Implications
Healthcare professionals should be aware of the evolving landscape of cell and gene therapies and the importance of collaborative efforts to enhance patient access.
Conclusion
The discussion highlights the need for a comprehensive approach to redefine value and access in cell and gene therapy, ensuring that these transformative treatments become more widely available.
Related Resources & Content
- the medicine maker, Roving Reporter Asks: How Are CGT Companies Rethinking Pricing and Reimbursement?, 2026 -- Roving Reporter Asks: How Are CGT Companies Rethinking Pricing and Reimbursement?
- the medicine maker, The Priorities for Cell and Gene in 2025 and 2026, 2025 -- The Priorities for Cell and Gene in 2025 and 2026
- the medicine maker, Champions of Cell and Gene Therapy, 2022 -- Champions of Cell and Gene Therapy
- CMS, CGT Access Model Frequently Asked Questions, 2025 -- CGT Access Model Frequently Asked Questions
- World Federation of Hemophilia, WFH gene therapy guidelines now published!, 2025 -- WFH gene therapy guidelines now published!
- the medicine maker — Breaking the Bottleneck of Affordability
- CGT Access Model Frequently Asked Questions | CMS
- WFH gene therapy guidelines now published! | World Federation of Hemophilia
- Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results - PMC
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
